OVIT 0.00 OncoVista Innovative Therapies, Inc.
| Range: | 1.0E-6-2.0E-4 | Vol Avg: | 1 | Last Div: | 0 | Changes: | 0 |
| Beta: | -44.86 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Fri Oct 26 2007 | Empoloyees: | 2 | ||
| CUSIP: | 68232J105 | CIK: | ISIN: | US68232J1051 | Country: | US | |
| CEO: | Dr. Alexander L. Weis Ph.D. | Website: | https://www.oncovista.com | ||||
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow